Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin with Neoadjuvant Chemoradiation for Esophageal Cancer
NCT03254511Phase 2Unknown
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of enoxaparin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Mashhad University of Medical Sciences. Primary endpoint: clinical response at 6 weeks. Status: unknown.
02
Drugs
enoxaparin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03254511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254511.